S468 with advanced NSCLC. Vandetanib targets clinically validated signaling pathways in NSCLC by inhibiting VEGFR-dependent tumor angiogenesis and EGFR-dependent tumor growth and survival. Vandetanib also inhibits RET kinase activity, which is an important growth driver in certain types of thyroid cancer. Phase I evaluation in patients with advanced solid tumors showed vandetanib was generally well tolerated at daily oral doses of ≤300 mg. Common adverse events included rash, diarrhea and asymptomatic QTc prolongation, all of which were controlled by standard management. A series of randomized, double-blind Phase II studies have investigated the efficacy of vandetanib in NSCLC, both as monotherapy and in combination with certain chemotherapies. A two-part study compared vandetanib (300 mg) with gefitinib (IRESSA™; 250 mg) in 2nd/3rdline NSCLC (in part B, eligible patients had the option to switch to the alternative treatment). The study achieved its primary efficacy objective: median progression-free survival (PFS) in part A was 11 weeks for vandetanib versus 8 weeks for gefitinib (HR=0.69, 95% CI = 0.50-0.96; 1-sided P=0.013). In 2nd-line NSCLC, vandetanib (100 or 300 mg) or placebo was assessed in combination with docetaxel. This study also achieved its primary objective, with vandetanib 100 mg + docetaxel demonstrating a significant prolongation of PFS versus docetaxel alone (HR=0.64, 95% CI = 0.38-1.05; 1-sided P=0.037). In 1st-line NSCLC, vandetanib (300 mg/day) ± carboplatin and paclitaxel (CP) was compared with CP + placebo. The primary objective was met, with vandetanib + CP prolonging PFS versus CP alone (HR=0.76, 95% CI = 0.50-1.15; 1-sided P=0.098): median PFS was 24 weeks (vandetanib + CP) and 23 weeks (CP). The vandetanib monotherapy arm was stopped early after a planned interim PFS analysis met the criterion for discontinuation (HR >1.33 vs CP). In all three studies, no overall survival benefit with vandetanib was seen. However, overall survival was a secondary endpoint in these studies and the effect of vandetanib on survival is potentially confounded by the impact of post-progression therapies. The positive outcomes from the Phase II studies have led to the initiation of Phase III evaluation of vandetanib in a broad population of patients with advanced NSCLC, including squamous and non-squamous cell histology (Table) . Clinical development is also ongoing in other tumor types, including hereditary medullary thyroid cancer, where encouraging antitumor activity has been observed. Ongoing Phase III studies of vandetanib in advanced NSCLC (study code) Vandetanib dose (mg/day) Primary objective Monotherapy Vandetanib versus placebo in patients previously treated with anti-EGFR therapy (6474IL0044) 300 Overall survival Vandetanib versus erlotinib in refractory NSCLC (6474IL0057) 300 PFS Combination regimens Vandetanib + docetaxel in 2nd-line NSCLC (6474IL0032) 100 PFS Vandetanib + pemetrexed in 2nd-line NSCLC (6474IL0036) 100 PFS PD3-3-5 Molecular Targeted Therapy: Beyond EGFR Inhibitors, Thu, 12:30 -14:15
also inhibits RET kinase activity, which is an important growth driver in certain types of thyroid cancer. Phase I evaluation in patients with advanced solid tumors showed vandetanib was generally well tolerated at daily oral doses of ≤300 mg. Common adverse events included rash, diarrhea and asymptomatic QTc prolongation, all of which were controlled by standard management. A series of randomized, double-blind Phase II studies have investigated the efficacy of vandetanib in NSCLC, both as monotherapy and in combination with certain chemotherapies. A two-part study compared vandetanib (300 mg) with gefitinib (IRESSA™; 250 mg) in 2nd/3rdline NSCLC (in part B, eligible patients had the option to switch to the alternative treatment). The study achieved its primary efficacy objective: median progression-free survival (PFS) in part A was 11 weeks for vandetanib versus 8 weeks for gefitinib (HR=0.69, 95% CI = 0.50-0.96; 1-sided P=0.013). In 2nd-line NSCLC, vandetanib (100 or 300 mg) or placebo was assessed in combination with docetaxel. This study also achieved its primary objective, with vandetanib 100 mg + docetaxel demonstrating a significant prolongation of PFS versus docetaxel alone (HR=0.64, 95% CI = 0.38-1.05; 1-sided P=0.037). In 1st-line NSCLC, vandetanib (300 mg/day) ± carboplatin and paclitaxel (CP) was compared with CP + placebo. The primary objective was met, with vandetanib + CP prolonging PFS versus CP alone (HR=0.76, 95% CI = 0.50-1.15; 1-sided P=0.098): median PFS was 24 weeks (vandetanib + CP) and 23 weeks (CP). The vandetanib monotherapy arm was stopped early after a planned interim PFS analysis met the criterion for discontinuation (HR >1.33 vs CP). In all three studies, no overall survival benefit with vandetanib was seen. However, overall survival was a secondary endpoint in these studies and the effect of vandetanib on survival is potentially confounded by the impact of post-progression therapies. The positive outcomes from the Phase II studies have led to the initiation of Phase III evaluation of vandetanib in a broad population of patients with advanced NSCLC, including squamous and non-squamous cell histology (Table) . Clinical development is also ongoing in other tumor types, including hereditary medullary thyroid cancer, where encouraging antitumor activity has been observed. Results: Out of 850 eligible pts, 26% (N=224) were ≥ 70 years of age (1.6% > 80 years). Median age for the elderly was 74 yrs; 44% were ≥ 75 yrs. Baseline characteristics of the elderly cohort were similar to the younger group except for a higher proportion of males (62% vs. 52%, P = 0.005). For the elderly pts, there was a trend towards superior response rate (29% vs. 17%, P = 0.067) and median PFS (5.9 mos vs. 4.9 mos, P = 0.063) with PCB when compared to PC, though there was no difference in overall survival (PCB = 11.3 mos; PC = 12.1 mos; P=0.4). Grades 3-5 toxicities (CTC version 2.0) were noted in 87% of elderly pts treated with PCB compared to 61% with PC (P < 0.001). Treatment-related death rates with PCB vs. PC were 6.3% vs. 1.8% (NS) for the elderly. Febrile neutropenia (6% vs. 0.9%), proteinuria (8% vs. 0) and hypertension (6% vs. 0.9%) were more common with PCB than PC among the elderly. When compared to younger pts, the elderly experienced more neutropenia (34% vs. 22%), bleeding (7.9% vs. 3.2%), proteinuria (7.9% vs. 1.3%), muscle weakness (7.9% vs. 2.2%) and motor neuropathy (3.5% vs. 0.6%) with PCB.
Conclusions:
The proportion of elderly patients in ECOG 4599 is the highest recorded among ECOG phase III studies for advanced NSCLC. Increased toxicity with the addition of bevacizumab in those ≥ 70 yrs may have contributed to the absence of survival benefit for PCB vs PC, but this observation is limited by its post-hoc, retrospective nature.
